Delving into the Latest Updates on Olendalizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lendalizumab (USAN), Olendalizumab (USAN), lendalizumab

+ [1]

Target

C5a

Mechanism

C5a inhibitors(complement C5a inhibitors)

Therapeutic Areas

Immune System Diseases

Active Indication

Graft Rejection

Inactive Indication

Acute Graft Versus Host DiseaseAntiphospholipid SyndromeGraft versus host disease in gastrointestinal tract+ [1]

Originator Organization

Alexion Pharmaceuticals, Inc.

Active Organization

Alexion Pharmaceuticals, Inc.

Inactive Organization

Immune Disease Institute, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 3876H

Source: *****

Sequence Code 3818L

Source: *****

Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a study, we evaluated the safety and efficacy of ALXN1007, a monoclonal antibody against C5a, in patients with newly diagnosed LGI acute GVHD receiving concomitant corticosteroid. Twenty-five patients were enrolled; one was excluded from the efficacy analysis based upon negative biopsy. Most patients (16/25, 64%) had acute leukemia; 52% (13/25) had an HLA-matched unrelated donor; and 68% (17/25) received myeloablative conditioning. Half the patients (12/24) had a high biomarker profile, Ann Arbor score 3; 42% (10/24) had high-risk GVHD per Minnesota classification. Day-28 overall response was 58% (13/24 complete response, 1/24 partial response), and 63% by Day-56 (all complete responses). Day-28 overall response was 50% (5/10) in Minnesota high-risk and 42% (5/12) in high-risk Ann Arbor patients, increasing to 58% (7/12) by Day-56. Non-relapse mortality at 6-months was 24% (95% CI 11-53). The most common treatment-related adverse event was infection (6/25, 24%). Neither baseline complement levels (except for C5), activity, nor inhibition of C5a with ALXN1007 correlated with GVHD severity or responses. Further studies are needed to evaluate the role of complement inhibition in GVHD treatment.

100 Deals associated with Olendalizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11331	-	-	DB14834

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Graft Rejection	Phase 2	-	Alexion Pharmaceuticals, Inc.	-
Acute Graft Versus Host Disease	Phase 1	FR	Alexion Pharmaceuticals, Inc.	14 Nov 2014
Acute Graft Versus Host Disease	Phase 1	US	Alexion Pharmaceuticals, Inc.	14 Nov 2014
Antiphospholipid Syndrome	Phase 1	ES	Immune Disease Institute, Inc.	-
Antiphospholipid Syndrome	Phase 1	IT	Immune Disease Institute, Inc.	-
Antiphospholipid Syndrome	Phase 1	BR	Immune Disease Institute, Inc.	-
Antiphospholipid Syndrome	Phase 1	GB	Immune Disease Institute, Inc.	-
Antiphospholipid Syndrome	Phase 1	JP	Immune Disease Institute, Inc.	-
Antiphospholipid Syndrome	Phase 1	US	Immune Disease Institute, Inc.	-
Antiphospholipid Syndrome	Phase 1	FR	Immune Disease Institute, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02245412 (GIGVHD, CTgov)	Phase 2	Acute Graft Versus Host Disease \| Graft versus host disease in gastrointestinal tract	25	ALXN1007 10 mg/kg once weekly (ALXN1007 10 mg/kg Once Weekly)	yyildpbous(alonsmlaqv) = ntxnpcnvsb ajqenzmddy (vxntznendv, immlbkfglk - kbhdcbjauu) View more	-	06 Oct 2017
NCT02245412 (GIGVHD, CTgov)	Phase 2		25	ALXN1007 20 mg/kg once weekly (ALXN1007 20 mg/kg Once Weekly)	yyildpbous(alonsmlaqv) = rmlrtzytid ajqenzmddy (vxntznendv, zojhexebmp - vzvdqgltar) View more	-	06 Oct 2017
NCT02128269 (CTgov)	Phase 2	Antiphospholipid Syndrome	9	Study Drug- ALXN1007	pymukfxkjx(enysyhrwxb) = srlfjisegu rvoyyhjazk (igbyoecoga, xfkvhpkxqf - jfryiczvcp) View more	-	13 Jul 2017